Literature DB >> 20220379

Are the proposed env mutations actually associated with resistance to maraviroc?

Annalisa Saracino, Laura Monno, Gaetano Brindicci, Giovanna Trillo, Maurantonio Altamura, Grazia Punzi, Antonella Lagioia, Gioacchino Angarano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20220379     DOI： 10.1097/QAI.0b013e3181ba46a6

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  5 in total

1.  Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B.

Authors:  Laura Monno; Annalisa Saracino; Luigia Scudeller; Grazia Punzi; Gaetano Brindicci; Maurantonio Altamura; Antonella Lagioia; Nicoletta Ladisa; Gioacchino Angarano
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

Review 2.  Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors.

Authors:  Chaozai Zhang; Ruohan Zhu; Qizhi Cao; Xiaohong Yang; Ziwei Huang; Jing An
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-04

Review 3.  Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.

Authors:  Caroline M Perry
Journal:  Drugs       Date:  2010-06-18       Impact factor: 9.546

Review 4.  Clinical use of CCR5 inhibitors in HIV and beyond.

Authors:  Bruce L Gilliam; David J Riedel; Robert R Redfield
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

5.  Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc.

Authors:  Saleta Sierra; J Nikolai Dybowski; Alejandro Pironti; Dominik Heider; Lisa Güney; Alex Thielen; Stefan Reuter; Stefan Esser; Gerd Fätkenheuer; Thomas Lengauer; Daniel Hoffmann; Herbert Pfister; Björn Jensen; Rolf Kaiser
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.